Literature DB >> 11035406

New therapies and delivery mechanisms for treatment of erectile dysfunction.

J L Pryor1, B Redmon.   

Abstract

Despite the successes of Viagra, the quest for new and better therapy for erectile dysfunction (ED) continues. In a recent survey of the first 220 patients placed on Viagra at our institution, 101 (46%) quit taking the drug: 76% of those who quit were not satisfied with the results. Patients clearly want an efficacious, safe, convenient medication with rapid onset. To meet these consumer demands, numerous new therapies are being developed. These include new oral medications, new intracavernosal pharmacotherapies, new delivery systems (such as novel intracorporal injectors and transdermal agents) and combination therapies. What is known about these new medications and delivery systems will be presented. Hopefully, from these innovations will come therapies that will improve the overall success and acceptance of treatment for ED. Since it is unlikely that any single agent will ever provide a solution for all men with ED, an expanded armamentarium of treatment options will greatly enhance the chances that any given man will be able to find a therapy that is both acceptable and appropriate to him. International Journal of Impotence Research (2000) 12, Suppl 4, S158-S162.

Entities:  

Mesh:

Year:  2000        PMID: 11035406     DOI: 10.1038/sj.ijir.3900597

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  2 in total

Review 1.  Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action.

Authors:  Ibrahim A Abdel-Hamid
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 2.  Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review.

Authors:  James Anaissie; Wayne Jg Hellstrom
Journal:  Res Rep Urol       Date:  2016-08-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.